Agonist
Back to library
GH SecretagogueSubcutaneous

Ipamorelin

Also known as: Ipa · NNC 26-0161

Selective ghrelin receptor agonist (GHSR-1a) and growth hormone secretagogue. Triggers pulsatile GH release without significant impact on cortisol, prolactin, or ACTH — a cleaner profile than older GHRPs.

At a glance

Half-life
2 hours
Common route
Subcutaneous
Typical dose range
100–300mcg
Stability (reconstituted)
30days refrigerated

Best timing

Fasted state preferred — carbohydrates and fat blunt GH pulse. 1–3x daily: AM, post-workout, and/or before bed.

Contraindications

  • Active cancer (any GH-axis activation)
  • Diabetic retinopathy (severe or proliferative)
  • Pregnancy
  • Carpal tunnel syndrome

Watch symptoms

  • Water retention, mild edema
  • Tingling or numbness in hands (carpal tunnel)
  • Increased appetite (ghrelin agonism)
  • Lethargy after injection
  • Headache or facial flushing

Citations

The primary literature.

  1. 01Ipamorelin, the first selective growth hormone secretagoguePubMed
  2. 02Ghrelin-mimetic peptide ipamorelin accelerates gastrointestinal transitPubMed

Related protocols

Stacks that use Ipamorelin.

Sleep & Recovery Stack

Pre-bed GH-pulse stack for deeper sleep and overnight recovery.

View protocol

Body Recomp Stack

Twelve-week tesamorelin + ipamorelin + BPC-157 protocol for lean recomposition.

View protocol
Back to library